IP Library Granted Patent US 8,465,754
Granted Patent B2
US 8,465,754 · App. 12/601,795 · Granted Jun 18, 2013

Patent

Inventors: Mineo Watanabe (Saitama, JP); Eiji Komatsu (Saitama, JP)
Assignee: Kitasato Daiichi Sankyo Vaccine Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,754
App. No.
12/601,795
Granted
Jun 18, 2013
Kind
B2
Abstract

An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by Bordetella parapertussis , comprising whole cells, whole-cell homogenate, or cell lysate of B. parapertussis as an immunogen, and methods for producing them.

Claims (8)

1. A method for preventing whooping cough caused by B. parapertussis in a subject, the method comprising steps of:

(a) culturing B. parapertussis cells at 35° C. to 37° C. using filamentous hemagglutinin (FHA) as an index to produce a B. parapertussis culture preparation with a final cell concentration of 10 10 cells/mL;

(b) inactivating the B. parapertussis cells by adding a formalin solution comprising formaldehyde at a final concentration of 0.2% to the B. parapertussis culture preparation; and

(c) administering the inactivated B. parapertussis cells as whole cells, as a whole-cell homogenate thereof, or as a cell lysate thereof to the subject.

2. A method for inducing immunity against B. parapertussis in a subject, the method comprising steps of:

(a) culturing B. parapertussis cells at 35° C. to 37° C. using filamentous hemagglutinin (FHA) as an index to produce a B. parapertussis culture preparation with a final cell concentration of 10 10 cells/mL;

(b) inactivating the B. parapertussis cells by adding a formalin solution comprising formaldehyde at a final concentration of 0.2% to the B. parapertussis culture preparation; and

(c) administering the inactivated B. parapertussis cells as whole cells, as a whole-cell homogenate thereof, or as a cell lysate thereof to the subject.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 49665 FRAME: 898. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 8, 2019
From: KITASATO DAIICHI SANKYO VACCINE CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 049686/0341 →
MERGER Recorded Jul 3, 2019
From: KITASATO DAIICHI SANKYO VACCINE CO., LTD.
To: DAIICHI SANKYO CHEMICAL PHARMA CO., LTD.
Reel/Frame 049665/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: THE KITASATO INSTITUTE
To: KITASATO DAIICHI SANKYO VACCINE CO., LTD.
Reel/Frame 028036/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2010
From: WATANABE, MINEO; KOMATSU, EIJI
To: THE KITASATO INSTITUTE
Reel/Frame 024396/0125 →
Priority Claims (1)
JP 2007-140721 · May 28, 2007 · national
Continuity (1)
Related Publication 20100260803A1 · Oct 14, 2010